
Quarterly ResultNov 4, 2026, 04:23 PM
Adaptive Biotechnologies Reports Q3 Profitability, Raises MRD Revenue Guidance
AI Summary
Adaptive Biotechnologies reported Q3 2026 financial results, achieving total company profitability ahead of expectations with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million. Total revenue was $83.9 million, down 11% YoY, but core MRD revenue grew 28% to $72.6 million, with the company raising its full-year MRD revenue guidance. Immune Medicine revenue saw a significant decrease. The company also highlighted progress in regulatory and clinical guidelines supporting its clonoSEQ product.
Key Highlights
- Adaptive Biotechnologies achieved total company profitability in Q3 2026 with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million.
- Q3 2026 revenue was $83.9 million, a decrease of 11% YoY, but excluding Genentech agreement revenue, it increased 39%.
- MRD revenue grew 28% YoY to $72.6 million in Q3 2026.
- Immune Medicine revenue was $11.3 million in Q3 2026, a decrease of 70% YoY.
- Delivered 39,587 clonoSEQ® tests in Q3 2026, an increase of 46% YoY.
- Raised full year 2026 MRD revenue guidance to $276 million - $286 million (30%-35% annual growth).
- Q3 2026 net income was $2.8 million, compared to $9.5 million in Q3 2025.
Price Impact
More from ADPT